secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0000950170-23-007037
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical reports Q4 net loss of $9.7M; Phase 2b wet AMD trial on track for Q2 2023
--------------------------------------------------------------------------------

- Q4 net loss $9.7M ($0.16/share) vs net income $18.7M ($0.31/share) in Q4 2021 on lower license revenue.
- Full-year 2022 net loss $32.9M ($0.55/share) vs net income $376K ($0.01/share) in 2021.
- Cash $48.3M at Dec 31, 2022; runway into Q2 2024.
- Phase 2b ODYSSEY trial of CLS-AX in wet AMD to start Q2 2023; comparator arm adjusted to on-label aflibercept per FDA draft guidance.
- Bausch + Lomb trained over 1,000 retinal physicians on SCS Microinjector for XIPERE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023007037/0000950170-23-007037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023007037/clsd-20230309.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer